Press Release

NeuroVision has announced completion of a nonexclusive license agreement with Janssen Research & Development LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, that will significantly expand the companies’ collaboration.

NeuroVision Imaging, LLC (NeuroVision) is developing a breakthrough, low cost, non-invasive, eye imaging system for measuring autofluorescence which can potentially detect amyloid beta (Aβ) plaque in the eye.

Retinal Imaging Test

Aβ plaque deposits in the brain are a hallmark sign of Alzheimer’s disease, and histological evidence shows that Aβ plaque also accumulates in the retina, the photoreceptor and nerve complex at the rear of the eye.

Clinical Research

Alzheimer’s begins creating changes in the brain (buildup of amyloid) as many as 20 years before symptoms occur. Early detection is essential.

Alzheimer's Disease

Our Story

NeuroVision is an integrated neuroscience company focused on delivering scientifically validated, diagnostic tests & biomarkers for early detection and monitoring of amyloid pathology related to Alzheimer’s Disease.   The company has developed a novel retinal imaging technology, which is currently being utilized in a number of clinical trials globally.

With access to unique datasets, we provide data aggregation services, analysis, biostatistics, and applications of machine learning algorithms to large repositories of images and other biomarker data seeking to advance the collective understanding and prediction capabilities for neurodegenerative diseases.

Alzheimer’s Facts

Alzheimer’s disease and other dementias will grow each year as the size and proportion of the population aged 65 and older continue to increase. By 2050, the number of people with Alzheimer’s disease is estimated to increase 300% and  reach 131 million.

Today it is the
leading cause of death

0 Million
Diagnosed Today
diagnosed every
seconds today

Projected Growth
every 20 years
Global Healthcare Costs
Billion today

0 Million
diagnosed in 2050